20-F: LakeShore Biopharma Navigates Legal Challenges and R&D Shifts Amidst Mixed Fiscal 2025 Results

LakeShore Biopharma reported a narrowed net loss and increased revenue in fiscal year 2025, driven by strong rabies vaccine sales, but faces ongoing litigation, significant R&D shifts, and internal control weaknesses.

Summary

• Net loss significantly narrowed to RMB100.0 million ($13.9 million) in fiscal year 2025 from RMB433.5 million in fiscal year 2024.
• Revenue increased by 7.2% to RMB615.0 million ($85.7 million) in fiscal year 2025, primarily driven by steady domestic economic recovery and increased sales volume of YSJATM rabies vaccine.
• Sold 7.8 million doses of YSJATM rabies vaccine in fiscal year 2025, representing an approximate 5.28% increase compared to the prior year period.
• Gross profit margin improved to 82.5% in fiscal year 2025 from 79.5% in fiscal year 2024, attributed to higher unit prices and lower per-unit costs.
• Research and development (R&D) expenses decreased by 51.7% to RMB146.4 million ($20.4 million) in fiscal year 2025, mainly due to the termination of the COVID-19 vaccine project and the advancement of PIKA rabies vaccine clinical trials.
• The independent auditor indicated substantial doubt about the company's ability to continue as a going concern due to net losses, accumulated deficits, and negative operating cash flow.
• Ongoing legal proceedings in the Cayman Islands and China against former chairperson Mr. Yi Zhang and his associates include arbitration claims totaling RMB919 million ($128 million) against Liaoning Yisheng and RMB83 million ($12 million) against Beijing Yisheng.
• Identified two material weaknesses in internal control over financial reporting as of March 31, 2025: a lack of sufficient qualified personnel knowledgeable in U.S. GAAP and SEC reporting, and a lack of policies for timely account reconciliation and disclosure.

Sentiment

Score: 3

Explanation: While the company showed revenue growth and narrowed its net loss, the underlying financial health remains precarious with substantial doubt about its going concern status, significant accumulated deficits, and negative operating cash flow. The ongoing, large-scale legal disputes and internal control weaknesses add considerable uncertainty and risk, overshadowing positive developments in product commercialization and R&D pipeline. The reliance on new financing and the high inventory levels also indicate underlying operational challenges.

Positives

• Net loss significantly narrowed to RMB100.0 million ($13.9 million) in fiscal year 2025 from RMB433.5 million in fiscal year 2024.
• Revenue increased by 7.2% to RMB615.0 million ($85.7 million) in fiscal year 2025, driven by steady domestic economic recovery and increased sales volume of YSJATM rabies vaccine.
• Gross profit margin improved to 82.5% in fiscal year 2025 from 79.5% in fiscal year 2024, attributed to higher unit prices and lower per-unit costs.
• YSJATM rabies vaccine sales volume increased by 5.28% to 7.8 million doses in fiscal year 2025.
• Phase III clinical trial for a simplified four-dose regimen for YSJATM rabies vaccine commenced in December 2024, with interim analysis expected in Q4 2025 and market approval in Q4 2026.
• PIKA rabies vaccine Phase III clinical trial in Pakistan and the Philippines met primary endpoints, demonstrating its potential to achieve accelerated protection and meet the WHO's goal of a one-week rabies vaccine regimen.
• Initiated Biologics License Application (BLA) submission to the Drug Regulatory Authority of Pakistan for conditional approval of PIKA rabies vaccine for post-exposure prophylaxis in November 2024.
• The U.S. Patent and Trademark Office issued a patent covering PIKA YS-HBV-002 in September 2023.
• PIKA YS-ON-001 completed its Phase I clinical study in China in 2023, showing good safety and tolerability among cancer patients.
• Successfully repaid the R-Bridge Loan of $40.0 million and accrued interest of $3.1 million in fiscal year 2024.
• Secured new financing lease agreements totaling RMB110 million ($15.3 million) in April 2025.
• Entered into a Share and Warrant Purchase Agreement with Crystal Peak Investment Inc. on July 8, 2025, for $15 million, with warrants fully exercised on a cashless basis on July 9, 2025, resulting in the issuance of 4,033,790 ordinary shares.

Negatives

• Incurred a net loss of RMB100.0 million ($13.9 million) for the fiscal year ended March 31, 2025.
• Accumulated deficit of $335.4 million as of March 31, 2025.
• Net cash used in operating activities was RMB121.0 million ($16.9 million) for fiscal year 2025.
• The independent auditor issued an audit opinion indicating substantial doubt about the company's ability to continue as a going concern.
• Ongoing legal proceedings and arbitration claims against former chairperson Mr. Yi Zhang and his associates, seeking aggregate payments of RMB919 million ($128 million) and RMB83 million ($12 million).
• Identified two material weaknesses in internal control over financial reporting as of March 31, 2025.
• Inventory level of finished products increased significantly to more than 12 months in fiscal year 2025, consistent with the vaccine industry in China, mainly due to industry policy adjustments, market supply-demand dynamics, and excess production capacity.
• Accounts receivable increased to RMB500.9 million ($69.8 million) as of March 31, 2025, primarily due to financial constraints and limited liquidity of local governments in certain regions, leading to payment delays.
• Impairment loss on intangible assets increased by RMB10.4 million ($1.4 million) in fiscal year 2025, primarily related to a long-held patent.
• Decision to terminate the PIKA YS-HBV-002 program following reassessment of its competitive landscape and commercial feasibility.
• Decision to put the PIKA rabies vaccine study on hold to evaluate commercial potential and regulatory requirements for the Southeast Asia region.
• Reliance on a single supplier for several key raw materials, increasing the risk of supply disruptions.
• Exposure to various legal and operational risks associated with doing business in China, including potential delisting under the HFCAA if PCAOB inspections are hindered in future years.
• Potential for product candidates to compete with the existing marketed product (YSJATM rabies vaccine).
• Limited operating experience and management teams in the international market.
• Leased property in Beijing is subject to a mortgage, posing a risk of inability to continue use upon foreclosure.
• Risk of fines and penalties under PRC laws for historical failure to make adequate contributions to social insurance and housing reserve fund for employees.
• Uncertainties regarding PRC tax treatment for indirect transfers and potential PRC tax on dividends/gains for foreign investors.
• Potential for dilution from future share issuances and warrant exercises.
• Warrants may expire worthless if the trading price of ordinary shares is less than $115.0 per share.

Risks

• Dependence on the current marketed rabies vaccine product (YSJATM rabies vaccine) to generate substantially all near-term revenue.
• Substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies worldwide, many with significantly greater financial resources and expertise.
• Auditor indicated substantial doubt about the company's ability to continue as a going concern due to net losses, accumulated deficits, and negative operating cash flows.
• Product candidates, once commercialized, may compete with the existing marketed product (YSJATM rabies vaccine).
• If the rabies vaccine industry in China does not grow as expected or declines, business expansion and results of operations could be materially and adversely affected.
• Commercial success of products depends on market acceptance by end-users, CDCs, and key opinion leaders (KOLs); failure to gain acceptance would limit revenue.
• The biopharmaceutical industry is highly regulated, with complex and changing policies; uncertainty in obtaining and maintaining regulatory approvals.
• Marketed product and product candidates may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Reliance on manufacturing facilities; any disruption or failure to meet GMP regulatory compliance or other requirements may have a material adverse effect.
• Failure to manage normal manufacturing capacity properly may materially and adversely affect revenues and profitability.
• Need to obtain substantial additional financing to fund operations; failure to obtain necessary capital when needed would force delays, limits, reductions, or termination of product development or commercialization efforts.
• Uncertainty regarding the issuance, scope, validity, enforceability, and commercial value of patent rights; inability to obtain and maintain broad patent protection could lead to direct competition.
• Ongoing global impacts and uncertainties of the COVID-19 pandemic or similar pandemics could adversely affect business.
• Exposure to legal and operational risks associated with doing business in China, including significant government oversight and potential intervention.
• Risk of delisting under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect auditors with presence in China in future years.
• PRC government's increased oversight and control over overseas securities offerings and foreign investment in China-based companies.
• Involvement in claims, disputes, litigation, and arbitration, particularly against former chairperson Mr. Yi Zhang, which could result in substantial costs and business disruption.
• Potential delisting from Nasdaq if the share price falls below US$1.00 for an extended period.
• Volatility in the price of ordinary shares due to various factors, including financial performance, regulatory changes, competition, and market sentiment.
• Dilution of shareholder ownership from future issuance of additional share capital in connection with financings, acquisitions, investments, or equity incentive plans.
• As an emerging growth company, may take advantage of certain reduced reporting requirements, potentially limiting information for investors.
• As a foreign private issuer, exempt from certain provisions applicable to U.S. domestic public companies, which may afford less protection to shareholders.
• As a controlled company, may rely on exemptions from certain corporate governance requirements, potentially limiting other shareholders' influence.
• Failure to remediate material weaknesses and implement and maintain an effective system of internal control over financial reporting could lead to inaccuracies in financial statements and loss of investor confidence.
• The growth and expansion of the business place a continuous, significant strain on operational and financial resources.
• Tax rate fluctuations and increased tax obligations due to multinational operations and potential future changes in tax law.
• Risk of being treated as a controlled foreign corporation (CFC) or passive foreign investment company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. Holders.
• Difficulties for overseas regulators to conduct investigations or collect evidence within China, limiting the ability to protect interests through U.S. courts.
• Risks related to real properties, including potential difficulties in continuing to lease or forfeiture of land use rights.
• Fines and penalties under applicable PRC laws and regulations for failure to make adequate contributions to social insurance and housing reserve fund for employees.
• Enhanced scrutiny over acquisition transactions by PRC tax authorities may negatively impact future acquisitions.
• Dependence on the continuing efforts of senior executives, key research and development personnel, and commercialization personnel; loss of their services could severely disrupt the business.
• Collaborations, in-licensing arrangements, joint ventures, strategic alliances, partnerships, or other strategic investment or arrangements may fail to produce anticipated benefits.
• Counterfeits of products and illegal vaccines could negatively affect sales and reputation and expose the company to liability claims.
• Failure to maintain and predict inventory levels in line with demand for marketed product could cause lost sales or excess inventory risks and holding costs.
• Decrease in the supply or an increase in the cost of raw materials could materially and adversely affect the business.
• Dealing with potentially harmful biological materials and other hazardous materials may cause environmental contamination or injury to others.
• Regulatory uncertainties in China could restrict the ability to grant share incentive awards to employees or consultants who are PRC citizens.
• Business operations are subject to the regulatory, economic, environmental, and competitive conditions and changes within the Southeast Asia region.
• Inflation in China and an increase in labor costs could negatively affect profitability and growth.
• Uncertainties with respect to the Business Combination and other indirect transfers of equity interests in PRC resident enterprises.
• Restrictions from transferring scientific data abroad and subject to regulations on human genetic resources.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the foreseeable future as it expands the sale of YSJATM rabies vaccine, advances clinical trials for product candidates, and seeks regulatory approvals. It plans to prioritize vaccine and protein therapeutic candidates within the infectious disease space, focusing on those with significant market potential and favorable competitive dynamics. The company believes its liquidity requirements will be satisfied by cash generated from operations and financing activities, but acknowledges that additional financing may be needed if commercialization is delayed or expenses increase.

Management Comments

• "The growth [in revenue] was primarily driven by the steady recovery of the domestic economy following the conclusion of the COVID-19 emergency, which facilitated a faster production and operational pace compared to the same period last year."
• "Despite a slight contraction in market size and heightened competition in 2024, which was largely due to the implementation of certain PRC regulations on procedures for managing rabies exposure, we generated a revenue increase of approximately 7% in the fiscal year ended March 31, 2025 from the prior fiscal year."
• "The decrease in R&D expenses was primarily attributable to... with the market contraction for COVID-19 vaccines resulting from the end of the COVID-19 pandemic, we decided to terminate our project to commercialize of COVID-19 vaccines... our R&D expenses for the PIKA rabies vaccine decreased by 45% compared to the previous year, which was primarily attributed to the advancement of the clinical trial and the completion of the majority of clinical follow-up visits in earlier phases, resulting in decreased related expenses for clinical trials as the work shifted to the less costly data analysis; and our R&D expenses for the YS-HBV vaccine also experienced an approximately 54% decrease, primarily driven by our decision to terminate the PIKA YS-HBV-002 program following reassessment of its competitive landscape and commercial feasibility."
• "We decided to put the study [PIKA rabies vaccine] on hold as we are currently evaluating the commercial potential and regulatory requirements for the Southeast Asia region."
• "Our management closely monitors uses of cash and cash balances and strives to maintain a healthy liquidity for our operations."
• "Going forward, we believe our liquidity requirements will be satisfied by cash generated from our operations and financing activities."
• "Our management has concluded that our internal control over financial reporting was not entirely effective as of March 31, 2025."

Industry Context

The rabies vaccine industry in China saw a significant increase in competition, with the number of providers rising from eight in 2020 to 12 in 2024. The market value of China's human rabies vaccine is expected to increase from RMB9.4 billion in 2021 to RMB22.1 billion in 2025 (CAGR of 23.8%), and to RMB33.3 billion in 2030 (CAGR of 8.5%). The company's PIKA rabies vaccine was designated by a WHO expert committee as an innovative vaccine, and its Phase III results met WHO's goal of a one-week rabies vaccine regimen. The company's decision to terminate the COVID-19 vaccine project and PIKA YS-HBV-002 program reflects market contraction and reassessment of the competitive landscape in those areas. The increase in finished product inventory level in fiscal year 2025 is consistent with the vaccine industry in China, mainly due to adjustments in industry policies, changes in market supply-demand dynamics, and prevalence of excess production capacity.

Comparison to Industry Standards

• YSJATM rabies vaccine is the first aluminum-free lyophilized rabies vaccine launched in China, offering advantages like less pain, injection site discomfort, and fever compared to certain other rabies vaccines in China.
• Head-to-head clinical studies showed YSJATM rabies vaccine had a lower rate of fever (18.4% vs 48.4% in children under 10) and adverse reactions (8.82% vs 24.03% in post-exposure patients) compared to other leading domestic products.
• YSJATM rabies vaccine showed comparable seroconversion rates (96% at day 14, 98.98% at day 42) to an imported lyophilized rabies vaccine, while being more affordable.
• PIKA rabies vaccine's accelerated one-week regimen is superior to conventional five-visit one-month or three-visit three-week regimens, significantly accelerating immunization generation from 28 days to 7 days, aligning with WHO's goal.
• PIKA rabies vaccine demonstrated higher seroconversion rates (50% vs 16.7% at day 7 under 1-1-1-1 regimen; 75% vs 16.7% under accelerated regimen) and stronger T-cell response compared to Rabipur (Novartis).
• PIKA YS-HBV-001 aims for a two-dose, one-month regimen, potentially improving compliance and reducing cost compared to current three-dose, six-month regimens.
• PIKA YS-HBV-001 preclinical studies showed increased HBsAg-specific IgG production and enhanced T-cell mediated immune response compared to aluminum-adjuvant HBsAg vaccine.
• PIKA YS-HBV-001 Phase I clinical studies indicated potential to induce multi-functional T cells, which are considered significant in clearing virus-infected cells, compared to Engerix (primarily mono-functional T cells).
• PIKA YS-ON-001 offers broad-spectrum anti-tumor activities, unlike PD-1 related checkpoint inhibitors which are more effective with high PD-L1 expression. Preclinical data showed PIKA YS-ON-001 was more efficient than anti-PD-1 or anti-PD-L1 antibodies in reducing tumor weight (>50% inhibition rate).
• PIKA YS-ON-001 has potential for combination therapies (radiotherapy, targeted therapies, checkpoint inhibitors, oncolytic viruses, chemotherapies) to enhance anti-cancer activity.
• PIKA YS-ON-001 is expected to have a better safety profile and marketability compared to adoptive cell-based immunotherapies (e.g., CAR-T) due to activating the patient's own immune response.

Management Changes

Corporate Governance

Legal Proceedings

• **FSD 400 of 2023 (Cayman Islands)**: Injunctions granted against former chairperson Mr. Yi Zhang and associates since December 2023, restraining them from acting as directors or chairperson. Company seeks declaratory and injunctive relief and damages. Mr. Zhang alleges improper ousting and breach of fiduciary duties by current/former directors. Proceedings ongoing.
• **FSD 318 of 2024 (Cayman Islands)**: Mr. Zhang filed a Writ in October 2024 against the company and 13 current/former directors and Apex Prospect Limited, seeking declarations on validity of board actions, setting aside share issuances (including to Apex and under share incentive plan), rectification of register, and injunctions against Apex and current directors. Mr. Zhang's ex parte injunction application was dismissed in January 2025. Proceedings ongoing, parties seeking consolidation.
• **Arbitration Claims (China)**: Two entities controlled by Mr. Zhang filed arbitration claims in May 2024 against Liaoning Yisheng, seeking RMB919 million ($128 million) for R&D services, accrued interests, and borrowings. Assets of Liaoning Yisheng (inventory, machinery, equipment, properties) valued at RMB919 million were frozen as a result.
• **Arbitration Claim (China)**: A claimant filed arbitration claims in May 2024 against Beijing Yisheng, seeking RMB83 million ($12 million) for fees and amounts from historical reorganization transactions.
• **Sales Contract Dispute (China)**: Liaoning Yisheng was involved in a sales contract dispute with Hebei Defense Biological Products Supply Center since 2018. The Supreme People's Court of Liaoning supported Liaoning Yisheng's claim for RMB2,465,807. RMB1,636,755 has been received, with a balance of RMB829,052 expected in 2026.
• **Labor Disputes**: The company was involved in labor disputes as of March 31, 2025.

Related Party Transactions

• Borrowed RMB311.4 million ($43.4 million) from Beijing Huarui Jingkai Real Estate Co., Ltd. (an affiliate of Apex Prospect Limited) in fiscal year 2025, with RMB7.6 million accrued interest.
• Borrowed RMB3.6 million ($0.5 million) from Apex Prospect Limited (a shareholder) in fiscal year 2025, with RMB0.01 million accrued interest.
• Purchased RMB1.8 million ($0.25 million) in services from HaiSong Zhiyuan (Beijing) Management Consulting Co., Ltd. (an entity controlled by the Chairman) in fiscal year 2025.
• Purchased RMB0.3 million ($0.04 million) in services and RMB0.1 million ($0.01 million) in property, plant and equipment from Beijing Yisheng Xingye Technology Co., Ltd. (an affiliate of Yisheng Biopharma Holdings Ltd.) in fiscal year 2025.
• In July 2023, purchased a vehicle for US$20,000 from Rui Mi (spouse of Mr. Yi Zhang), which was purchased back by Rui Mi in March 2024.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from future equity financings and warrant exercises. Share price volatility due to financial performance, legal disputes, and China-related risks. Less protection due to foreign private issuer and controlled company status.
• **Employees**: Share-based compensation plans aim to attract and retain talent. Historical inadequate social insurance/housing fund contributions were rectified, but the potential for future penalties exists.
• **Customers (CDCs)**: Sales to county-level CDCs are the primary revenue source. Delays in payments from CDCs due to local government financial constraints impact cash flow.
• **Suppliers**: Reliance on single suppliers for key raw materials poses supply disruption risk.
• **Creditors**: Substantial doubt about going concern status and ongoing legal disputes could affect the ability to service debt. New financing leases and borrowings indicate continued reliance on debt.

Next Steps

• Finish interim analysis of Phase III clinical trial for simplified four-dose regimen for YSJATM rabies vaccine in Q4 2025.
• Obtain market approval for simplified four-dose regimen for YSJATM rabies vaccine in Q4 2026.
• Discuss with NMPA to launch more advanced trials for PIKA rabies vaccine in China.
• Continue to evaluate commercial potential and regulatory requirements for PIKA rabies vaccine in the Southeast Asia region.
• Proceed with more advanced clinical studies for PIKA YS-HBV-001 in China and other countries.
• Implement measures to remediate identified material weaknesses in internal control over financial reporting, including hiring qualified personnel and developing U.S. GAAP accounting policies.
• Increase marketing efforts to drive end-customer demand and adjust production batches to align with sales trends for YSJATM rabies vaccine.
• Expand commercialization team, marketing service providers, and county-level CDC coverage in China.
• Seek potential partnerships and licensing to facilitate commercialization of YSJATM rabies vaccine in certain Southeast Asian countries.
• Strategically accelerate the development and commercialization of other PIKA-based product candidates.
• Continue to monitor and manage cash flows and seek additional financing as needed.
• Address ongoing legal proceedings and arbitration claims.

Key Dates

Recommendation

The company faces severe financial and operational headwinds, including an auditor's 'going concern' warning, substantial accumulated deficits, and persistent negative operating cash flow. The ongoing, high-value legal disputes with the former chairman and related entities introduce significant financial uncertainty and potential liabilities that could severely impact liquidity and operations. Furthermore, identified material weaknesses in internal controls over financial reporting raise concerns about the reliability of financial disclosures. While revenue growth and R&D progress are positive, these fundamental risks, coupled with intense market competition and high inventory levels, suggest a highly speculative investment with a strong likelihood of further value erosion. A seasoned investor would likely seek to exit or avoid this position until these foundational issues are demonstrably resolved.

Keywords

Biopharmaceutical, Vaccines, Rabies Vaccine, PIKA Adjuvant, Immuno-oncology, Hepatitis B Vaccine, China, SEC Filing, 20-F, Clinical Trials, Drug Development, Corporate Governance, Financial Performance, Risk Management, Nasdaq, Going Concern, Legal Proceedings, Internal Controls